ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.915
      0.15%
      Bitcoin
      65,186.77
      0.07%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Context Therapeutics Inc (CNTX)

      7. Context Therapeutics Inc (CNTX) News

      CNTX

      Context Therapeutics (CNTX)

      Context Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CNTX
      DateTimeSourceHeadlineSymbolCompany
      12/17/20216:06AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CNTXContext Therapeutics Inc
      12/09/20216:00PMGlobeNewswire Inc.Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNASDAQ:CNTXContext Therapeutics Inc
      12/06/20214:47PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      12/06/20214:45PMGlobeNewswire Inc.Context Therapeutics Inc. Announces Closing of $31.25 Million Private PlacementNASDAQ:CNTXContext Therapeutics Inc
      12/02/20214:07PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CNTXContext Therapeutics Inc
      12/02/20214:01PMGlobeNewswire Inc.Context Therapeutics® Reports Third Quarter 2021 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
      12/01/20216:30PMGlobeNewswire Inc.Context Therapeutics Inc. Announces $31.25 Million Private PlacementNASDAQ:CNTXContext Therapeutics Inc
      11/19/20219:00AMGlobeNewswire Inc.Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNASDAQ:CNTXContext Therapeutics Inc
      11/18/202111:32AMEdgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:CNTXContext Therapeutics Inc
      11/18/202111:32AMEdgar (US Regulatory)Sec Staff Action/letter (sec Staff)NASDAQ:CNTXContext Therapeutics Inc
      11/01/20214:32PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
      11/01/20214:10PMEdgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNTXContext Therapeutics Inc
      11/01/20214:04PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
      11/01/20214:02PMGlobeNewswire Inc.Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal OfficerNASDAQ:CNTXContext Therapeutics Inc
      10/27/20217:30AMGlobeNewswire Inc.Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast CancerNASDAQ:CNTXContext Therapeutics Inc
      10/22/20214:05PMGlobeNewswire Inc.Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment OptionNASDAQ:CNTXContext Therapeutics Inc
      10/19/20217:14PMGlobeNewswire Inc.Context Therapeutics® Announces Pricing of Initial Public OfferingNASDAQ:CNTXContext Therapeutics Inc
      10/29/20207:30AMGlobeNewswire Inc.Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New InvestorsNASDAQ:CNTXContext Therapeutics Inc
      12/16/20197:30AMGlobeNewswire Inc.NexImmune Appoints Sol Barer as Chairman of the Board of DirectorsNASDAQ:CNTXContext Therapeutics Inc
      12/03/20198:00AMGlobeNewswire Inc.Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975NASDAQ:CNTXContext Therapeutics Inc
      11/08/20198:00AMGlobeNewswire Inc.Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting an...NASDAQ:CNTXContext Therapeutics Inc
      09/17/20198:00AMGlobeNewswire Inc.Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-497...NASDAQ:CNTXContext Therapeutics Inc
      09/04/201911:11AMGlobeNewswire Inc.CORRECTION - Centrexion TherapeuticsNASDAQ:CNTXContext Therapeutics Inc
      09/04/20198:00AMGlobeNewswire Inc.Centrexion Therapeutics Announces CNTX-4975, CNTX-0290 and CNTX-6970 Data Presentations at PAINWeek 2019 National ConferenceNASDAQ:CNTXContext Therapeutics Inc
      07/18/20197:30AMGlobeNewswire Inc.Centrexion Therapeutics to Present New Positive Clinical Trial Results on Streamlined CNTX-4975 Administration TechniquesNASDAQ:CNTXContext Therapeutics Inc
      06/11/20197:30AMGlobeNewswire Inc.Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual...NASDAQ:CNTXContext Therapeutics Inc
      04/29/20198:25AMGlobeNewswire Inc.Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference...NASDAQ:CNTXContext Therapeutics Inc
      03/27/20197:30AMGlobeNewswire Inc.Centrexion Therapeutics Announces Publication of Phase 2 Efficacy Data on CNTX-4975 for Treatment of Moderate to Severe Knee ...NASDAQ:CNTXContext Therapeutics Inc
      03/07/20197:30AMGlobeNewswire Inc.Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy o...NASDAQ:CNTXContext Therapeutics Inc
      12/05/20187:30AMGlobeNewswire Inc.Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Tre...NASDAQ:CNTXContext Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:CNTX